Quarterly ResultMay 6, 2026, 05:27 PM
LifeMD Q1 Net Loss Widens to $9.65M; Out of Credit Covenant Compliance
AI Summary
LifeMD, Inc. reported a significant increase in net loss attributable to common stockholders, reaching $9.65 million for Q1 2026, compared to a $0.96 million loss in Q1 2025. Telehealth revenue slightly decreased to $50.16 million. The company also disclosed non-compliance with a Consolidated Interest Coverage Ratio covenant under its new $30 million credit facility, primarily due to a 34% increase in selling and marketing expenses. Discussions with Citizens Bank for an amendment or waiver are ongoing.
Key Highlights
- Net loss attributable to common stockholders widened to $9.65 million in Q1 2026 from $0.96 million in Q1 2025.
- Telehealth revenue decreased by 1.4% to $50.16 million in Q1 2026 from $50.89 million in Q1 2025.
- Operating loss from continuing operations increased to $8.93 million in Q1 2026 from $1.18 million in Q1 2025.
- Selling and marketing expenses rose by 34% to $29.87 million in Q1 2026.
- LifeMD is out of compliance with the Consolidated Interest Coverage Ratio covenant for its $30 million credit facility.
- Cash balance decreased to $34.48 million as of March 31, 2026, from $36.79 million at December 31, 2025.
- Total stockholders' equity decreased to $15.04 million from $23.16 million over the same period.
- The company has $44.6 million available under its At Market Issuance Sales Agreement.